SciClone Pharmaceuticals (Holdings) Limited (HK:6600) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SciClone Pharmaceuticals (Holdings) Limited has announced that 12,500 Share Options from its Post-IPO Option Plan have lapsed as of June 15, 2024, according to the plan’s rules. Following this lapse, the company reports a total of 630,543,012 Shares in issue and 66,218,552 Share Options still in issue, comprised of different tranches under its Option Incentive and Post-IPO Option Plans.
For further insights into HK:6600 stock, check out TipRanks’ Stock Analysis page.